**9. Conclusions**

Availability of generics and easier access to these drugs can impact the outcomes in oncology settings. The low-priced and affordable generic medicines and biosimilars can improve the adoption and compliance with treatment options in cancer care. However, the low price of these drugs is often construed as compromise in quality. There are myriad perceptions for the use of generics and biosimilars in routine practice. The perceptions are different among physicians in high- and low-income countries; these can possibly be due to differences in regulations and policies, educational opportunities and available drug information sources. Factors like cost, quality, effectiveness, and safety impact the understanding for and adoption of generics and biosimilars. There are several challenges in the substitution and switch from originator products to generics and biosimilars. The widespread and confident adoption of generics requires collaborative efforts of prescribers, healthcare professionals, payers, and the manufacturers of these agents.

**145**

**Author details**

Amit Garg1

provided the original work is properly cited.

\*, Deepak CSN1

1 Dr. Reddy's Laboratories Ltd., Hyderabad, India

2 Independent Medical Affairs Consultant, New Delhi, India

\*Address all correspondence to: amitgarg@drreddys.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

and Tarveen Jandoo2

*Perceptions and Challenges for Adoption of Generics and Biosimilars in Oncology*

*DOI: http://dx.doi.org/10.5772/intechopen.85587*
